Anhedonia News and Research

RSS

Adolescent psychotic experiences lack uniformity

Psychotic experiences in adolescence appear to be quite distinct and vary widely from individual to individual, study findings indicate.

3 Oct 2013

Depression highlighted as nonadherence risk in bipolar patients

The presence of residual depressive symptoms may result in patients with bipolar disorder being nonadherent to their medication, study findings suggest.

12 Sep 2013

Psychotic experiences ‘not always pathologic’

A study backs the existence of “healthy schizotypy,” in which psychotic experiences do not lead to mental illness.

10 Sep 2013

Routine depression screening for adults not recommended in primary care settings

For adults with no apparent symptoms of depression, routine screening is not recommended in primary care settings because of the lack of high-quality evidence on the benefits and harms of screening for depression, according to new evidence-based guidelines from the Canadian Task Force on Preventive Health Care published in CMAJ.

14 May 2013

Study challenges role of serotonin in depression, opens possibilities for new therapies

A new study from the University of Maryland School of Medicine suggests that depression results from a disturbance in the ability of brain cells to communicate with each other.

19 Mar 2013

Researchers identify an exceptional mouse model of schizophrenia

Researchers at the Institute for Comprehensive Medical Science, Fujita Health University and the National Institute for Physiological Sciences, Japan, along with colleagues from 9 other institutions, have identified an exceptional mouse model of schizophrenia.

7 Feb 2013

Depression, anxiety not linked to psychosis transition

Depression and anxiety disorders are common in patients at increased clinical risk for psychosis, but do not appear to influence transition to full-blown psychosis, say UK researchers.

5 Dec 2012

Reduced hedonic capacity in euthymic bipolar patients

Euthymic patients with bipolar disorder and remitted patients with major depressive disorder show reduced hedonic capacity compared with mentally healthy individuals, Italian researchers report.

8 Nov 2012

Psychotic depression now fulfills the criteria for a valid psychiatric syndrome

The number of studies reporting significant and clinically relevant differences between psychotic depression (PD) and non-PD has increased considerably over the past decades. This summary of the current evidence suggests that PD now fulfils the criteria for a valid psychiatric syndrome.

14 Jul 2012

Novel molecular mechanism responsible for most important symptom of major depression

Stanford University School of Medicine scientists have laid bare a novel molecular mechanism responsible for the most important symptom of major depression: anhedonia, the loss of the ability to experience pleasure.

12 Jul 2012

Adiponectin reduces depression-like symptoms in mice

A hormone with anti-diabetic properties also reduces depression-like symptoms in mice, researchers from the School of Medicine at the UT Health Science Center San Antonio reported today.

10 Jul 2012

Despite improvements, disparities in diagnosis and treatment of depression remain

Despite improvements to diagnostic tools and therapies in the two last decades, significant disparities in the diagnosis and treatment of depression remain, according to Rutgers research published online by the American Journal of Public Health; print, February 2012.

21 Dec 2011

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Study explores link between specific temperament traits and clinical events after heart attack

This study explores for the first time the potential predictive power of Cloninger's temperament traits on prognosis in patients after an acute coronary syndrome admission.

19 May 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Study establishes direct link between morphine abstinence and depressive-like symptoms

Opiate abuse is a chronic disorder and maintaining abstinence represents a major challenge for addicts.

1 Feb 2011

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.